RecruitingPhase 1Phase 2NCT00722228

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

Sponsor

Hadassah Medical Organization

Enrollment

50 participants

Start Date

Jul 1, 2008

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Colorectal, Cancer Gastric Cancer Ovarian Cancer Lung Cancer Melanoma Kidney Cancer

Summary

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a cancer vaccine made from the patient's own tumor cells (or donor tumor cells) to help the immune system fight advanced, spreading cancers. **You may be eligible if...** - You have metastatic (spreading) melanoma, breast, ovarian, colorectal, stomach, lung, or kidney cancer - You are 18 years of age or older - You have already tried at least one chemotherapy treatment that did not work - You are in reasonably good physical health (able to carry out light activity) - Your blood counts and kidney/liver function are within acceptable ranges **You may NOT be eligible if...** - You are under 18 years old - You are pregnant - Your doctors estimate you have less than 3 months to live Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.